REG - Medpal AI PLC - Issue of Fee Shares

Medpal AIAnnouncement

20/04/2026 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260420:nRST1854Ba&default-theme=true

RNS Number : 1854B  Medpal AI PLC  20 April 2026

20 April 2026

 

MedPal AI plc

("MedPal AI" or the "Company")

 

Issue of Fee Shares

MedPal AI Plc (AIM: MPAL, FRA: Z1N), the UK digital health and AI company,
announces that it has issued 3,600,000 new ordinary shares ("Fee Shares") in
lieu of £90,000 of cash in respect of advisory fees incurred by the Company.
The Fee Shares have been valued at 2.5p per share, equivalent to the price per
share issued pursuant to the placing announced by the Company on 17 April
2026.

The Fee Shares will, when issued, rank pari passu in all respects with the
existing ordinary shares of the Company, including the right to receive all
dividends and other distributions declared, made or paid after their date of
issue.

Application will be made to the London Stock Exchange for the Fee Shares to be
admitted to trading on AIM ("Admission"). It is expected that Admission will
become effective and dealings in the Fee Shares will commence at 8.00 a.m. on
24 April 2026.

Following Admission, the Company's issued ordinary share capital will consist
of 616,041,036 ordinary shares of £0.0002 each, with one voting right per
share. No ordinary shares will be held in treasury. The total number of voting
rights in the Company following Admission will therefore be 616,041,036, which
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer                     Via Square1 Consulting

 Cairn Financial Advisers LLP            (Nomad)             +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Oak Securities (a trading name of Merlin Partners LLP)      +44 (0) 20 3973 3678

 Tim Dainton/Calvin Man

 Clear Capital Markets                                       +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                                          +44 (0) 20 7929 5599

 David Bick                                                  +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company building the MedPal Health OS -
a vertically integrated, closed-loop platform spanning AI wellness, clinical
services, and automated pharmacy fulfilment. Its core app aggregates data from
over 100 wearable devices and health apps (including Apple Health, Fitbit,
Garmin, and Whoop) into a unified health profile, offering personalised,
non-clinical lifestyle guidance through its AI wellness coach and acting as
the consumer front door to the Company's clinical and pharmacy services.

 

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages BD Rowa VMAX
robotic dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

 

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms. The Company's LEI is
984500EDP8B0A14CBA61.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEAKKBDPBKDAQB



            Copyright 2019 Regulatory News Service, all rights reserved